Kymera Therapeutics to Participate in Upcoming June Investor Conferences

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, has announced its participation in three major investor conferences in June 2025:

- Jefferies Global Healthcare Conference in New York on June 5 at 8:10 a.m. ET
- Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 10 at 3:20 p.m. ET
- Wolfe Research Virtual Biotech Day on June 26 (one-on-one meetings only)

Live webcasts of the presentations will be available on Kymera's website under the Investors section, with replays archived for later viewing.

WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: 

• Jefferies Global Healthcare Conference in New York, NY on June 5 at 8:10 a.m. ET;
• Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL on June 10 at 3:20 p.m. ET; and
• Wolfe Research Virtual Biotech Day on June 26, one-on-one meetings only.
  

Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events. 

About Kymera Therapeutics 
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn. 

Availability of Other Information About Kymera Therapeutics 
For more information, please visit the Kymera website at https://www.kymeratx.com/ or follow Kymera on X (@KymeraTx) and LinkedIn (Kymera Therapeutics). Investors and others should note that Kymera communicates with its investors and the public using the Company website, including, but not limited to, corporate disclosures, investor presentations, FAQs, Securities and Exchange Commission (SEC) filings, and press releases, as well as on X and LinkedIn. The information that Kymera posts on its website or on X or LinkedIn could be deemed to be material information. As a result, the Company encourages investors, the media and others interested to review the information that Kymera posts there on a regular basis. The contents of Kymera’s website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. 

Investor and Media Contact: 
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300 

FAQ

What investor conferences will KYMR attend in June 2025?

Kymera Therapeutics will attend three conferences: Jefferies Global Healthcare Conference (June 5), Goldman Sachs Global Healthcare Conference (June 10), and Wolfe Research Virtual Biotech Day (June 26).

Where can investors watch Kymera Therapeutics' (KYMR) conference presentations?

Live webcasts will be available under the 'News and Events' section of Kymera's website (www.kymeratx.com), with replays archived for later viewing.

What type of medicines is Kymera Therapeutics (KYMR) developing?

Kymera Therapeutics is developing a new class of oral small molecule degrader medicines focused on treating immunological diseases.

What is the current development stage of Kymera Therapeutics (KYMR)?

Kymera Therapeutics is a clinical-stage biopharmaceutical company.